Seattle Genetics is an innovator in the field of biotechnology. It develops treatments for various types of cancer. It uses the novel method of anti-body based therapy. It has developed one of the industry’s premier antibody-drug conjugates which harness the ability of antibodies to send cell-killing agents directly into infected cancer cells. The drug known as ADCETRIS is the company’s number one product. It was developed in tandem with Takeda Pharmaceutical Company Limited. It is in the new class of drugs that are available to people in more than 60 countries in the world. It treats Hodgkin lymphoma and large cell lymphoma.
Seattle Genetics was founded by Clay Siegall, and it was founded in Bothell Washington in 1998. It has a stable pipeline of treatments for solid tumors and cancers of the blood. Companies such as AbbVie, Bayer, Celldex, Genentech, Pfizer, Astellas and GlaxoSmithKline have partnered with Seattle Genetics.
Seattle Genetics has achieved positive data in early tests of treatment of cancer in a solid tumor setting. It remains to be seen if the early results can be backed up by more trials. The company states that its new antibody-drug conjugate called SGN-LIV1A has achieved results in treating patients who have negative metastatic breast cancer. This type of cancer has proven difficult to treat over the years. The trial was performed at the San Antonio Breast Cancer Symposium.
Seattle Genetics is testing four candidates in its series of trials that are aimed to eliminating solid tumors. The successful drug contains a LIV-1-targeted monoclonal antibody. This drug has the power to send a cell-killing payload into cancer cells to eliminate them. The drug was determined to be a success because it had a 37% rate of response in patients. Furthermore, these patients were no longer responding to other forms of treatment. This makes this drug a new potential last hope for many suffering from this terrible form of cancer. Every year 1.67 million people are diagnosed with breast cancer. Many of them are triple negative meaning they have a poorer chance of survival and their disease will progress more rapidly. Seattle Genetics and Clay Siegall hope to pioneer new treatments for helping these people.